A detailed history of Vanguard Group Inc transactions in Castle Biosciences Inc stock. As of the latest transaction made, Vanguard Group Inc holds 1,494,176 shares of CSTL stock, worth $32.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,494,176
Previous 1,461,481 2.24%
Holding current value
$32.5 Million
Previous $31.5 Million 4.94%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$18.06 - $25.3 $590,471 - $827,183
32,695 Added 2.24%
1,494,176 $33.1 Million
Q4 2023

Feb 14, 2024

BUY
$12.19 - $22.43 $269,313 - $495,545
22,093 Added 1.53%
1,461,481 $31.5 Million
Q3 2023

Nov 14, 2023

BUY
$13.28 - $20.3 $158,921 - $242,930
11,967 Added 0.84%
1,439,388 $24.3 Million
Q2 2023

Aug 14, 2023

BUY
$11.66 - $26.0 $274,243 - $611,520
23,520 Added 1.68%
1,427,421 $19.6 Million
Q1 2023

May 15, 2023

BUY
$19.47 - $28.49 $217,616 - $318,432
11,177 Added 0.8%
1,403,901 $31.9 Million
Q4 2022

Feb 10, 2023

BUY
$18.08 - $30.0 $2.57 Million - $4.26 Million
141,991 Added 11.35%
1,392,724 $32.8 Million
Q3 2022

Nov 14, 2022

BUY
$22.51 - $34.32 $898,981 - $1.37 Million
39,937 Added 3.3%
1,250,733 $32.6 Million
Q2 2022

Aug 12, 2022

BUY
$16.0 - $45.99 $553,104 - $1.59 Million
34,569 Added 2.94%
1,210,796 $26.6 Million
Q1 2022

May 13, 2022

BUY
$33.17 - $46.98 $444,013 - $628,874
13,386 Added 1.15%
1,176,227 $52.8 Million
Q4 2021

Feb 14, 2022

SELL
$39.06 - $67.58 $130,733 - $226,190
-3,347 Reduced 0.29%
1,162,841 $49.9 Million
Q3 2021

Nov 12, 2021

BUY
$60.13 - $77.6 $2.34 Million - $3.03 Million
38,996 Added 3.46%
1,166,188 $77.6 Million
Q2 2021

Aug 13, 2021

BUY
$50.07 - $76.78 $56.4 Million - $86.5 Million
1,127,192 New
1,127,192 $82.7 Million

Others Institutions Holding CSTL

About CASTLE BIOSCIENCES INC


  • Ticker CSTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 26,297,000
  • Market Cap $572M
  • Description
  • Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...
More about CSTL
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.